Huntington??s disease: present treatments and future therapeutic modalities
Authors:
- Raphael M. BonelliRBRaphael M. Bonelli
- Gregor K. WenningGWGregor K. Wenning
- Hans P. KapfhammerHKHans P. Kapfhammer
- 1 March 2004
- journal article
- review article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 19 (2) , 51-62
Abstract
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless to date, except in a slight symptomatic relief. Even the discovery of the gene related to HD in 1993 has not effectively advanced treatments. This article is essentially a review of available double-blind, placebo-controlled trials of therapy for this condition which also includes relevant open label trials. Unfortunately, HD research has tended to concentrate on the motor aspects of the disorder, whereas the major problems are behavioural (e.g. dementia, depression, psychosis), and the chorea is often least relevant in terms of management. We conclude that there is definitely poor evidence in management of HD. The analysis of the 24 best studies fails to result in a treatment recommendation of clinical relevance. Based on data of open-label studies, or even case reports, we recommend riluzole, olanzapine and amantadine for the treatment of the movement disorders associated with HD, selective serotonin reuptake inhibitors and mirtazapine for the treatment of depression, and atypical antipsychotic drugs for HD psychosis and behavioural problems. Moreover, adjuvant psychotherapy, physiotherapy and speech therapy should be applied to supply the optimal management. Finally, some cellular mechanisms are discussed in this paper because they are essential for future neuroprotective modalities, such as minocycline, unsaturated fatty acids or riluzole.Keywords
This publication has 100 references indexed in Scilit:
- Huntingtin aggregation and toxicity in Huntington's diseaseThe Lancet, 2003
- Cognitive Correlates of Obsessive and Compulsive Symptoms in Huntington’s DiseaseAmerican Journal of Psychiatry, 2001
- Noncompliance: an overviewDMW - Deutsche Medizinische Wochenschrift, 2001
- Goal-directed secondary motor tasks: Their effects on gait in subjects with Parkinson diseaseArchives of Physical Medicine and Rehabilitation, 2000
- Acute Challenge with Apomorphine in Huntingtonʼs DiseaseClinical Neuropharmacology, 1995
- Serum haloperidol concentration and choreiform movements in Huntington's diseaseNeurology, 1988
- Therapeutic experience with transdihydrolisuride in Huntington's diseaseNeurology, 1986
- Tetrabenazine and movement disordersNeurology, 1981
- Choline therapy in Huntington choreaNeurology, 1977
- BACLOFEN AND LITHIUM IN HUNTINGTON'S CHOREAThe Lancet, 1973